Our study showed that LY2510924 effectively disrupted the CXCL12/CXCR4 axis and reversed stroma-mediated extrinsic resistance to FLT3 inhibitors in FLT3-ITD-AML, mainly through the downregulation of stroma-induced MAPK activation. Here, CXCR4 is linked to acute myeloid leukemia.